Daniel Rea

10.8k total citations
126 papers, 4.3k citations indexed

About

Daniel Rea is a scholar working on Cancer Research, Oncology and Genetics. According to data from OpenAlex, Daniel Rea has authored 126 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Cancer Research, 69 papers in Oncology and 44 papers in Genetics. Recurrent topics in Daniel Rea's work include Breast Cancer Treatment Studies (67 papers), Estrogen and related hormone effects (38 papers) and HER2/EGFR in Cancer Research (34 papers). Daniel Rea is often cited by papers focused on Breast Cancer Treatment Studies (67 papers), Estrogen and related hormone effects (38 papers) and HER2/EGFR in Cancer Research (34 papers). Daniel Rea collaborates with scholars based in United Kingdom, Canada and Netherlands. Daniel Rea's co-authors include John M.S. Bartlett, Christos Markopoulos, Caroline Seynaeve, Annette Hasenburg, Lucinda Billingham, Hein Putter, Cornelis J.�H. van de Velde, Christopher Poole, S. Bowden and E.T.M. Hille and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Daniel Rea

120 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Rea United Kingdom	32	2.5k	1.8k	1.2k	999	971	126	4.3k
Christos Markopoulos Greece	33	2.5k 1.0×	1.7k 0.9×	1.0k 0.8×	1.0k 1.0×	615 0.6×	198	4.7k
Marjanka K. Schmidt Netherlands	42	2.1k 0.8×	2.0k 1.1×	1.3k 1.1×	1.4k 1.4×	484 0.5×	160	4.8k
P. Pronzato Italy	32	2.5k 1.0×	1.1k 0.6×	731 0.6×	595 0.6×	884 0.9×	231	4.4k
Diana Crivellari Italy	37	3.3k 1.3×	2.1k 1.1×	694 0.6×	681 0.7×	1.2k 1.2×	152	4.9k
Jennifer A. Doherty United States	27	2.9k 1.2×	1.2k 0.7×	2.1k 1.8×	596 0.6×	2.9k 2.9×	109	6.0k
Robert Mennel United States	22	4.2k 1.7×	3.3k 1.8×	1.6k 1.3×	952 1.0×	1.2k 1.3×	47	6.7k
Agustí Barnadas Spain	34	2.0k 0.8×	1.2k 0.7×	1.6k 1.4×	383 0.4×	789 0.8×	141	4.1k
Vincent Caggiano United States	23	2.5k 1.0×	1.8k 1.0×	736 0.6×	658 0.7×	579 0.6×	55	3.8k
Anil Potti United States	31	2.1k 0.9×	1.4k 0.8×	2.7k 2.2×	504 0.5×	1.2k 1.2×	103	5.3k
Luboš Petruželka Czechia	31	2.0k 0.8×	771 0.4×	872 0.7×	542 0.5×	1.6k 1.7×	181	3.8k

Countries citing papers authored by Daniel Rea

Since Specialization

Citations

This map shows the geographic impact of Daniel Rea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Rea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Rea more than expected).

Fields of papers citing papers by Daniel Rea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Rea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Rea. The network helps show where Daniel Rea may publish in the future.

Co-authorship network of co-authors of Daniel Rea

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Rea. A scholar is included among the top collaborators of Daniel Rea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Rea. Daniel Rea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bartlett, John M.S., Ranelle Salunga, Linda de Munck, et al.. (2025). Validation of minimal risk of recurrence classification by the Breast Cancer Index in early stage breast cancer. npj Breast Cancer. 12(1). 21–21.

Goodwin, Pamela J., Bingshu E. Chen, Karen A. Gelmon, et al.. (2023). Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. Journal of Clinical Oncology. 41(35). 5356–5362. 11 indexed citations

Bartlett, John M.S., Keying Xu, Gregory R. Pond, et al.. (2023). Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR+ breast cancer in the TEAM trial.. Journal of Clinical Oncology. 41(16_suppl). 509–509. 1 indexed citations

Fernando, Indrajit, Siân Lax, S. Bowden, et al.. (2023). Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity. Clinical Oncology. 35(6). 397–407. 1 indexed citations

Bartlett, John M.S., Dennis C. Sgroi, Kai Treuner, et al.. (2022). Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. Clinical Cancer Research. 28(9). 1871–1880. 25 indexed citations

Kristeleit, Hartmut, Vivek Misra, Mark Baxter, et al.. (2022). Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience – A Multicenter Retrospective Study. Oncology. 100(12). 666–673. 2 indexed citations

Sgroi, Dennis C., Kai Treuner, Yi Zhang, et al.. (2022). Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Breast Cancer Research. 24(1). 90–90. 5 indexed citations

Goodwin, Pamela J., Ryan J.O. Dowling, Marguerite Ennis, et al.. (2021). Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectrum. 5(5). 12 indexed citations

Bartlett, John M.S., Ikhlaaq Ahmed, Kai Treuner, et al.. (2021). 11P A Breast Cancer Index (BCI) prognostic model for N0 HR+ breast cancer optimized for late distant recurrence. Annals of Oncology. 32. S25–S25. 1 indexed citations

10.

Kuerer, Henry M., Marie-Jeanne T.F.D. Vrancken Peeters, Daniel Rea, et al.. (2017). Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials. Annals of Surgical Oncology. 24(10). 2855–2862. 40 indexed citations

11.

Maguire, Sabine, et al.. (2017). Agents, mechanisms and clinical features of non-scald burns in children: A prospective UK study. Burns. 43(6). 1218–1226. 11 indexed citations

12.

Bartlett, John M.S., Ikhlaaq Ahmed, Meredith M. Regan, et al.. (2017). HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. European Journal of Cancer. 79. 129–138. 15 indexed citations

13.

Puglisi, Fabio, et al.. (2015). Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review. Cancer Treatment Reviews. 43. 36–49. 7 indexed citations

14.

Stephen, Jacqueline, Gordon Murray, David Cameron, et al.. (2014). Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. British Journal of Cancer. 111(12). 2242–2247. 10 indexed citations

15.

Rea, Daniel, Richard Gray, S. Bowden, et al.. (2013). Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer. European Journal of Cancer. 49. 17 indexed citations

16.

Water, W. van de, Christos Markopoulos, Cornelis J.�H. van de Velde, et al.. (2012). Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer. Obstetrical & Gynecological Survey. 67(7). 415–416. 21 indexed citations

17.

Hughes, Timothy P., Gabriel Étienne, Cármino Antônio De Souza, et al.. (2012). Nilotinib induces deeper molecular responses vs continued imatinib in patients with ph+ chronic myeloid leukemia (CML) with detectable disease after ≥ 2 years on imatinib: ENESTcmr 12-months results. Haematologica. 97. 239–239.

18.

Velde, Cornelis JH van de, Daniel Rea, Caroline Seynaeve, et al.. (2011). Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. The Lancet. 377(9762). 321–331. 264 indexed citations

19.

Bartlett, John M.S., Cassandra Brookes, Tammy Robson, et al.. (2011). Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology. 29(12). 1531–1538. 142 indexed citations

20.

Caine, Graham J., Paul Stonelake, Daniel Rea, & Gregory Y.H. Lip. (2003). Coagulopathic complications in breast cancer. Cancer. 98(8). 1578–1586. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact